M. Bonsignore (Palermo, Italy), R. L. Riha (Edinburgh, United Kingdom)
Energy expenditure in obese OSAS patients before and after CPAP therapy
M. Rizzi, M. Pecis, A. Andreoli, D. Legnani (Milano, Italy)
|   |
5-lipoxygenase pathway: one of the mediators of early atherosclerosis in obstructive sleep apnea syndrome?
B. Lefebvre, J. L. Pepin, J. P. Baguet, J. Bessard, X. Fonrose, K. Riedweg, J. Tonini, G. Bessard, P. Levy, F. Stanke-Labesque (Grenoble, France)
| |
Increased angiotensin II (Ang II) and oxidants are critical for angiogenesis and endothelial receptor for oxidized LDL (LOX-1) expression in obstructive sleep apnea (OSA) patients
Y. Nakamura, T. Kizawa, K. Hosokawa, S. Takahashi, S. Sakurai, H. Inoue (Morioka, Japan)
| |
Consequences of hypoxia-reoxygenation fenomen in the patients with OSAS
T. Ulukavak Ciftci, O. Kokturk, S. Demirtas (Ankara, Turkey)
| |
Effect of blood mononuclear cells from patients with obstructive sleep apnea-hypopnea syndrome on apoptosis of human umbilical vein endothelial cells
C. X. Ye, X. L. Gao, D. F. Li, R. J. Cen, S. H. Luo (Guang Zhou, China)
| |
TNF-alpha, IL-6 and adiponectin serum levels in obese patients: comparison between simple snorers and SAS
R. Bossi, C. Baldessari, V. Betti (Milan, Italy)
| |
Influence of CPAP on the immunological mechanism of atherogehesis in SAS patients
R. Bossi, C. Baldessari, V. Betti, P. Bonara (Milan, Italy)
| |
Does low plasma adiponectin level affect cardiovasculer risk in obstructive sleep apnea syndrome?
O. Kokturk, T. Ulukavak Ciftci, A. Kanbay, Y. Tavil, N. Bukan (Ankara, Turkey)
| |
Are there genetic influences in obstructive sleep apnea by polymorphisms of the endothelin-receptor-subtype-a-gene?
D. Buck, K. Diefenbach, T. Penzel, I. Fietze, I. Roots (Berlin, Germany)
| |
Plasma orexin-A levels in patients with obstructive sleep apnea syndrome
K. Aksu, S. Firat Guven, B. Ciftci, T. Ulukavak Ciftci, S. Aksaray, F. Aksu, T. Sipit (Ankara, Turkey)
| |
Association of IL-6 and TNFα and leptin receptor (LEPR) gene polymorphism with IL-6 and TNFα serum level in obstructive sleep apnea syndrome (OSAS) patients
U. Demkow, K. Popko, E. Gorska, R. Plywaczewski, A. Stoklosa, P. Sliwinski, M. Wasik, D. Gorecka (Warsaw, Poland)
| |
Cardiovascular risk, insulin resistance and metabolic syndrome in patients with obstructive sleep apnea
R. Tkacova, Z. Dorkova, A. Molcanyiova, I. Tkac (Kosice, Slovakia)
| |
The relationship between some oxidative stress markers and metabolic cardiovascular risk factors in the blood of different stage obstructive sleep apnea persons
S. Cofta, E. Wysocka, H. Batura-Gabryel, L. Torlinski (Poznan, Poland)
| |
The influence on hyperlipemia and abnormal glucose metabolism in obstructive sleep apnea-hypopnea syndrome (OSAHS)
Y. Wu, Y. Zhou, Y. Yan, Z. Li (Guangzhou, China)
| |
Exhaled nitric oxide in obstructive sleep apnea (OSA) patients: short and long term response to automatic positive airway pressure (APAP) therapy
P. Pinto, C. Barbara, R. Dias, C. Canhao, J. Teixeira, M. J. Marques Gomes (Lisbon, Portugal)
| |
Total cholesterol and low density lipoprotein (LDL) cholesterol in obstructive sleep apnoea (OSA)
I. Papaioannou, G. Twigg, A. Vazir, M. Kemp, J. Hooper, A. Simonds, M. Morrell, M. Polkey (London, United Kingdom)
| |
Visfatin levels in sleep apnea syndrome
G. Trakada, P. Steiropoulos, T. Gkioka, A. Pataka, G. Kouliatsis, I. Sotiriou, A. Koukouvitis, D. Bouros (Alexandroupolis, Greece)
| |
Serum leptin levels in obstructive sleep apnoea patients
M. Drummond, J. C. Winck, J. T. Guimarães, A. C. Santos, A. Marques (Oporto, Portugal)
| |
Oxydative stress in obstructive sleep apnea (OSA). Exhaled breath condensate (EBC) measurements (H2O2) in the follow-up of patients under CPAP. First results
M. Westhoff, O. Barbara, L. Patric (Hemer, Germany)
| |
Insulin resistance and patterns of continuous glucose monitoring in sleep apnoea patients: relationship with nocturnal hypoxemia and CPAP therapy
F. Mormile, F. Macagno, T. Schirinzi, A. Petrone, M. Andreani, A. Di Flaviani, M. T. Madeo, P. Borboni (Rome, Italy)
| |